Press & Media Coverage
Catch up on our latest press coverage
Quarterly Activity Report and Appendix 4C for 30 June 2023
Highlights include: MagSense® HER2 Phase 1 Study achieves enrolment target Expands collaboration with Siemens Healthineers Dr. Isaac Bright appointed as CEO MELBOURNE – Imagion Biosystems (ASX:IBX),
Imagion expands collaboration with Siemens Healthineers to United States
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has
Imagion set to complete the MagSense® HER2 Phase 1 Study
Highlights Study achieves enrolment target Study to formally close to new enrolments on 31 July Study results support further clinical development as MRI imaging agent
Imagion Announces New CEO
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, is pleased to announce it has appointed Isaac
[White Paper] Molecular Imaging: Changing the Way We Look at Cancer
Australasian Biotechnology | Vol 33 Number 1 Imagion authored a white paper, published in the April issue of Australasian Biotechnology, discussing current medical imaging technologies,
Chairman’s Address to Shareholders and Q&A Session at 2023 Annual General Meeting
Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session
Watch our latest media coverage
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.